Abstract. The common acute lymphoblastic leukemia antigen (CALLA) has been detected in biological fluids using a radioimmunoassay based on the inhibition of binding of 125I-labeled monoclonal anti-CALLA antibody to glutaraldehyde-fixed NALM-1 cells.
Introduction
The common acute lymphoblastic leukemia antigen (CALLA)' has been described initially as a cell surface antigen present on leukemic blasts in patients with the common type of acute lymphoblastic leukemia (c-ALL) or with chronic myelocytic leukemia in lymphoid blast crisis (1) (2) (3) (4) (5) (6) (7) . In addition, normal lymphocyte precursors appear to express CALLA, especially during bone marrow regeneration (8) , but this antigen has not been detected on immature myeloid precursors (9) . Outside the hematopoietic system, CALLA has been identified on the surface of tubular and glomerular fetal and adult kidney cells (10) as well as on glioma (11) and melanoma (12) cells. Biochemically, CALLA has been characterized as a single polypeptide chain with an approximate molecular weight of 100 kD (13) .
In this work, we report for the first time the presence of CALLA in the serum of patients with c-ALL. The In all cases the serum was collected after blood coagulation, followed by centrifugation at 2,000 g for 15 min. In two cases of c-ALL with previously identified elevated serum CALLA levels, blood samples were collected into three tubes; one without anticoagulant, one with EDTA, and one with heparin. The tubes were stored at room temperature, and serum or plasma was taken from each tube 1, 24, and 48 h after blood collection (the centrifuged blood was mixed gently after each removal of plasma or serum samples).
Monoclonal antibody and target cells. The MAb A-12 used in the CALLA RIA was obtained from a fusion between lymphocytes of a BALB/c mouse immunized with NALM-1 cells and cells from the myeloma line P3-NSI/l-Ag4 (19) . As previously reported (15), MAb A12 is of IgG1 subclass and reacts with the same epitope as the first described MAb anti-CALLA termed J5 (16) . MAb A-12 was purified from hybridoma ascitic fluid by ion exchange chromatography, and labeled with 1251 by the chloramine T method.
Exponentially growing NALM-1 cells were fixed by a 10-min incubation at 25°C in 0.12% glutaraldehyde. The fixed cells retained their antigenicity for at least 1 mo when stored at 4°C in 0.15 M phosphate-buffered saline, pH 7.4 (PBS), containing 5% fetal bovine serum and 0.02% azide.
RIA. 30-40% of '25I-labeled MAb A-12 (50 nCi representing about 6 ng of protein) was cell-bound after a 5-h incubation with 5 X 104 glutaraldehyde-fixed NALM-1 cells at 4°C. This binding was quantitatively inhibited up to 95% by NP-40 extracts of NALM-1 cells but not by extracts from CALLA-negative lines as demonstrated by the standard inhibition curve and controls presented in Fig. I A.
In the routine RIA procedure, radiolabeled MAb A-12 diluted in 50 jul of PBS containing 1 mg/ml of bovine serum albumin was incubated for 16 h at 25°C with 50 ul of either 20 times concentrated culture fluid from the NALM-1 cell line or dilutions of patients' sera. 50,000 glutaraldehyde-fixed NALM-1 cells were then added for a further incubation of 16 h at 4°C. The cells were washed with PBS containing I mg/ml of bovine serum albumin, and the cell-bound radioactivity was measured in a gamma-counter. Dilutions of a reference serum from a patient with a high CALLA level as well as from a pool of serum from normal individuals were always tested in parallel to calibrate each series of new serum samples to be analyzed.
Determination of S'-nucleotidase activity. Assay of 5'-nucleotidase (EC 3.1.3.5) was performed as previously described (20) . Briefly, pellets obtained by a 100,000 g centrifugation of I ml of patient serum or 200 Al of the serum supernatant were resuspended in 4 ml of 50 mM Tris-HCl buffer, pH 7.5, containing 2 mM 5'-AMP and 8 mM MgCl2, and incubated for 20 min at 37°C. The reaction was stopped by the addition of 0.8 ml of 30% ice-cold trichloroacetic acid. The released inorganic phosphate was measured colorimetrically at 820 nm on 2-ml aliquots.
Results
In a first series of experiments, the newly developed CALLA RIA was used to demonstrate the release of this antigen into culture fluids by two cell lines, NALM-I (14) and Daudi (21) , known to express CALLA on the cell surface. As shown in Fig. 1 Fig. 2 . The mean inhibition for the control sera was 13.2% with a SD of 7.3.
We selected an arbitrary limit of 35% inhibition (3 SD over the mean inhibition value of the control sera) to operationally define positive and negative results. Under these 1883 Circulating Common Acute Lymphoblastic Leukemia Antigen conditions, 34/42 (81%) cases of c-ALL were positive, whereas none of the normal serum samples nor any of the 12 cases of T-ALL were positive. Only one of the 26 cases of AML gave a borderline inhibition, and only one of the 10 cases of AUL gave a significant inhibition of 51%.
Furthermore, sera from six patients with c-ALL were tested before treatment and after induction of complete remission. A marked drop of the CALLA values after treatment was observed in the four cases who had elevated values at presentation (Fig. 3) .
In two c-ALL cases in which serum as well as EDTA and heparin plasma samples were obtained and separated from blood at different time intervals after blood collection (1, 24, and 48 h), we did not observe any difference in CALLA inhibition, neither between serum and plasma values nor between samples prepared by early or late centrifugations.
These results suggest that the CALLA detected in serum or plasma has not been released from blood cells after blood collection.
Serum samples from six patients with elevated CALLA inhibition values were centrifuged at 100,000 g for 1 h at 40C.
The CALLA was measured by RIA both in the supernatant and the pellets. Virtually all of the CALLA inhibiting activity (95-100%) was found in the pellet fractions. In addition, pellet and supernatant fractions from CALLA-positive sera were tested for the presence of 5'-nucleotidase, an enzyme known to be associated with cell membrane (20 
Discussion
In this context, it is of interest that a release of Ia antigens in the supernatant of cultured murine B-cell lymphomas has been observed (22) . In this case also, the released antigen was recovered in the pellet after a centrifugation at 100,000 g.
The clinical significance of circulating CALLA remains to be ascertained. Along this line, it should be emphasized that all the cases of c-ALL tested here had been diagnosed by previous bone marrow examination and had >90% leukemia blasts. However, some of the cases had relatively low numbers of leukemic blasts in peripheral blood. There was no correlation between the CALLA levels in the serum and the number of malignant cells in the circulation. For instance, six cases with CALLA inhibition values ranging from 40 to 88% (mean = 53) had <5,000 blasts/fl of blood (mean = 1,900); whereas four cases with >20,000 blasts/,l of blood (mean = 37,800) had < 35% of CALLA inhibition value (mean = 24). This absence of correlation suggests that the major part of the CALLA material detected in the circulation is released by noncirculating leukemic cells. An alternative explanation could be that the blasts from each case of c-ALL have a different rate of CALLA release.
Prospective and sequential CALLA assays should be performed in the serum of patients with c-ALL in remission to determine how early in the relapse this antigen becomes detectable in the circulation, and if sequential CALLA assays could substitute for some of the repeated bone marrow aspirations.
